Clinical Trial Update: Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating Tenalisib for metastatic triple-negative breast cancer and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Tenalisib (tenalisib)

Snippet

Sponsor: Rhizen Pharmaceuticals SA | Conditions: Triple Negative Breast Cancer (TNBC) | Phase 2 | Status: RECRUITING